

Author Index Volume 60 July-December 1999

- Affandi, B., 281
 Aisien, A.O., 249
 Alvarado, G., 45
 Amaral, E., 361
 Andersen, L.F., 337
 Arbogast, K., 15
 Archer, D.F., 15, 151
 Arévalo, M., 65, 357
 Aura, M., 243
- Baker, J., 15
 Ballagh, S.A., 255
 Bangou, J., 167
 Bassol, S., 45
 Bastola, S., 31
 Bhattarai, L., 31
 Bradshaw, K.D., 255
 Brandao, M.A.F., 305
 Bravo, C., 9
- Calaf, J., 243
 Callahan, M.M., 15, 71
 Carlos, G., 45
 Casado, M.E., 9
 Chanda, O., 9
 Chasan-Taber, L., 145
 Chaudhary, I., 39
 Chen-Mok, M., 15, 155
 Christiansen, E., 337
 Clark, S., 223
 Clark, V.A., 289
 Creinin, M.D., 263
 Cromie, M.A., 179, 201
 Croxatto, H.B., 9
 Curhan, G.C., 145
- Day, J., 31
 Delgado, S.R., 233
 Di, X., 161
 Diaz, S., 9, 45
 Dominik, R., 71, 315
 Dusterberg, B., 269
- Edgren, R.A., 313
 El-Husseini, M., 87, 93, 101
 Ellertson, C., 119, 167, 223, 233
 El-Nahal, N., 87, 93, 101
 Elomaa, K., 275, 299
 Elul, B., 167, 223, 233
 Endrikat, J., 269
 Espins, J.J., 243
- Faúndes, A., 361
 FemCap Investigators' Group,
 The, 71
 Fernandez, V., 45
 Fetis, G., 9
 Fong, Y.-F., 51, 173
 Frezieres, R.G., 289
- Gabelnick, H.L., 15
 Garceau, R.J., 179
 Garcia-Barrios, C., 233
 Garg, S., 361
 Gerlinger, C., 269
 Gispert, M., 243
 Goco, N., 345
 Godwin, A.J., 81
 Gonzalez, B., 345
 Goyaux, N., 107
 Grimes, D.A., 57
 Gu, S., 161
 Guengant, J.-P., 167
 Guerra, M.O., 305
 Guful, F., 249
- Harper, C., 233
 Hassan, E.O., 87, 93, 101
 Heimbürger, A., 233
 Hertz-Picciotto, I., 137
 Hopkins, N.K., 201, 209
 Hubacher, D., 345
- Inayatullah, A., 39
- Jain, S., 111
 Jain, J.K., 353
 Jaisamraun, U., 25
 Jennings, V., 65, 357
 Jespersen, J., 337
 Jha, R., 31
 Jiang, J., 161
 Juhakoski, A., 299
- Kaewrudee, S., 25
 Kaper, R.F., 1
 Kaunitz, A.M., 177, 179
 Koide, S.S., 111
 Korver, T., 281
 Kumar, P.G., 111
- Lahteenmaki, P., 275, 299
 LaLoraya, M., 111
 Langer, A., 233
- Lavin, P., 9
 Ledesma, L., 45
 Li, Y., 161
 Lippman, J.S., 81
 Liu, C.Q., 309
 Lu, S.H., 309
 Lukhando, M., 223
 Lunelle Study Group, The, 179
- Madsbad, S., 337
 Mant, J., 331
 Massai, R., 9
 Mauck, C., 15, 71
 Mazoni, A.S.B., 305
 McMullen, S., 31, 155
 Meckstroth, K.R., 353
 Meyers, A., 321
 Miranda, P., 9
 Mishell, Jr., D.R., 177, 353
 Moo-Young, A., 299
 Morales, E., 45
 Morrison, C.S., 15
 Muia, E., 223
 Mutihir, J.T., 249
- Nelson, A.L., 289
 Nichols, M., 255
- Oleen-Burkey, M., 215
 Olenja, J., 223
 Olson, W., 81
- Painter, R., 353
 Park, M., 353
 Peralta, O., 9
 Peters, V.M., 305
 Petersen, K.R., 337
 Pymar, H.C., 263
- Qian, S.-Z., 1
- Rahimy, M.H., 189, 201, 209
 Rai, C., 31
 Raymond, E., 45, 137
 Redmond, G., 81
 Rehan, N., 39
 Reinprayoon, D., 25
 Rivera, R., 31, 155
 Rodriguez-Espinosa, J., 243
 Rosenberg, M.J., 321
 Roy, V., 321
 Ruebig, A., 269

Ryan, K.K., 189, 209

Saleh, S.I., 299

Sang, G.W., 1

Saxena, D., 111

Schiavon, R., 233

Schoenbach, V., 137

Schulz, K.F., 57

Schwartz, J.L., 263

Shrestha, S., 31

Shulman, L.P., 215

Silva, M.A., 9

Sinai, I., 65, 357

Singh, K., 51, 173

Skouby, S.O., 337

Sonosiain, R., 243

Stampfer, M.J., 145

Stanczyk, F.Z., 255, 313

Steiner, M., 137

Stock, R., 15

Strowitzki, T., 281

Suherman, S.K., 281

Suvisaari, J., 299

Taneepanichskul, S., 25

Taylor, D., 345

Thadhani, R., 145

Thapa, S., 31

Thonneau, P., 107

Thornycroft, I.H., 255

Tong, D.M., 201

Trussell, J., 119, 137, 315

Ujah, I.A.O., 249

Vald, S.P., 9

Vanrell, C., 243

Veazey, R., 15

Vega, C., 243

Vessey, M., 331

Waller, D., 361

Walsh, T.L., 289, 315

Wang, Z.X., 309

Weber, M.E., 255

Weiner, D.H., 71

Welffens-Ekra, C., 107

Wheless, A., 137

Wilke, R.J., 215

Willett, W.C., 145

Wraxall, B.G.D., 289

Yac-Soumah, F., 107

Yuan, Y., 309

Zanevald, L., 361

Zepeda, A., 9

Zhang, C., 161

Zheng, S.-R., 1

Zheng, H.-M., 1

Zhiying, P., 15

Subject Index Volume 60 July-December 1999

- Abortion practices, complications, 107
- Acceptability, nonoxynol-9 spermicide preparations, 45
- Acceptability and satisfaction, Lunelle™, 177
- Acidform,
 - acid-buffering bioadhesive gel, 361
 - vaginal tolerance, 361
- Acne,
 - effect of ethinyl estradiol + levonorgestrel, 255
 - effect of ethinyl estradiol + norethindrone acetate, 255
 - effect of ethinyl estradiol + norgestimate, 81
- Adenomyosis, treatment with levonorgestrel-releasing IUD, 173
- Androgens, effect of OCs, 255
- Anemia, prevalence in family planning clinics, 93
- Antibiotic prophylaxis, IUD insertion, 57
- Antiestrogens, effect on uterine activity, 111
- Attitudes about emergency contraception, 223, 233

- Back disorders, effect of OC use, 331
- Barrier contraceptive, FemCap®, 71
- Bone density, effect of levonorgestrel, 161
- Bone metabolism, effect of levonorgestrel, 161

- Cervical ectopy, effect of DMPA, 19
- Checklist, safe initiation of DMPA, 31
- Client characteristics, effect on TCu 380A discontinuations, 155
- Clinical study,
 - Cyclofem, 87
 - ethinyl estradiol + desogestrel, 269
 - Implanon implant, 1
 - Mesigyna, 87
 - Norplant implants, 1, 39
 - progesterone-releasing vaginal ring, 9
- Clinical trial,
 - Lunelle, 177, 179, 189, 201, 209, 215
 - medical abortion regimens, 119
- Coital frequency, influence on risk of pregnancy, 137
- Commentary, gonane progestins nomenclature, 313
- Complications, induced abortion methods, 107
- Condom failure, detection of PSA, 289
- Continuation rates,
 - DMPA users, 345
 - Norplant implants, 39
- Contraceptive failure rates, perfect users vs. perfect use, 315
- Cost-effectiveness analysis, trimonthly OC regimen, 263

- Cycle variability, influence on risk of pregnancy, 137
- Cyclofem®, clinical study, 87

- Depot-medroxyprogesterone acetate (DMPA), effect on vaginal epithelium and cervical ectopy, 15
- Diaphragm, Ortho All-Flex, 71
- Discontinuation reasons, use of TCu 380A, 155
- DMPA (depot-medroxyprogesterone acetate)
- DMPA + estradiol cypionate, 177, 179, 189, 201, 209, 215
- DMPA initiation, checklist for safe delivery, 31
- DMPA users, continuation rates, 345

- Effectiveness, postcoital contraception, 201
- Efficacy, medical abortion, 119
- Embryo toxicity, lapachol (rat), 305
- Emergency contraception,
 - ethinyl estradiol + levonorgestrel, 243
 - knowledge, attitudes and practices, 223, 233
- Endometrial histology, effect of ethinyl estradiol + desogestrel, 151
- Estradiol,
 - effect on uterine activity, 111
 - pharmacokinetics, 209
- Ethinyl estradiol + desogestrel,
 - clinical study, 132, 269
 - effect on endometrial histology, 151
- Ethinyl estradiol + gestodene,
 - clinical study, 269
 - effect on insulin sensitivity, 337
 - ovulatory potential of follicles, 275
- Ethinyl estradiol + levonorgestrel,
 - clinical study, 321
 - effect on androgen profile, 255
 - postcoital contraception, 243
- Ethinyl estradiol + norethindrone, clinical study, 179
- Ethinyl estradiol + norgestimate,
 - clinical study, 321
 - effect on insulin sensitivity, 337
 - treatment of acne vulgaris, 81
- Extended use of OC pills, cost-effectiveness analysis, 263

- Failure rates, perfect users vs. perfect use, 93
- Family planning clinics, prevalence of anemia, 93
- Female condom study, 137
- Female sterilization, minilaparotomy, 249
- FemCap®, safety and efficacy, 71
- Ferritin level,
 - effect of combined OC, 101

- effect of TCU 380A, 101
- Fertile window,
 - fixed formula, 357
 - use of TwoDay Algorithm, 65
- Gestational hypertensive disorders, effect of pregravid OC use, 145
- Gonane progestins, nomenclature, 313
- Gynefix[®], late uterine perforation, 55
- Hemoglobin level,
 - effect of combined OC, 101
 - effect of TCU 380A
- Identify fertile window,
 - fixed formula, 12-5
 - use of TwoDay Algorithm, 65
- Implanon[®] implant,
 - clinical study, 1
- Implant contraceptive,
 - etonogestrel, 1, 281
 - levonorgestrel, 1, 25, 39, 161, 281
- Injectable contraceptive,
 - depot-medroxyprogesterone acetate, 15, 31, 345
 - DMPA + estradiol cypionate, 87, 177, 179, 189, 201, 209, 215
 - northisterone enanthate + estradiol valerate, 87
- Insulin sensitivity, OC users, 337
- Interceptive effect, lapachol (rat), 305
- Intrauterine device (IUD),
 - Gynefix, 55
 - Multiload Cu 250, 281
 - TCU 380A, 9, 101, 155
- IUD (intrauterine device)
- IUD insertion, prophylactic antibiotics, 1
- IUD use, effect on back disorders, 331
- IUS (intrauterine system)
- Knowledge level, emergency contraception, 223, 233
- Lapachol, interceptive effect (rat), 305
- Late onset of OC treatment, effect on ovulatory potential of follicles, 275
- Levonorgestrel-releasing IUS,
 - effect on uterine myomas, 51
 - treatment of adenomyosis, 173
- Lipid metabolism,
 - effect of etonogestrel, 281
 - effect of levonorgestrel, 281
 - effect of Multiload Cu 250, 281
- Lunelle[™], clinical trial, 177, 179, 189, 201, 209, 215
- Male subdermal implants, 7 α -methyl-19-nortestosterone, 299
- Medical abortion,
 - efficacy, 119
 - mifepristone + misoprostol, 167
 - misoprostol, 353
 - tamoxifen + misoprostol, 353
- Medical abortion methods, 119
- Medroxyprogesterone acetate, pharmacokinetics, 201, 209
- Mefenamic acid, effect on irregular uterine bleeding, 25
- Mesigyna[®], clinical study, 87
- 7 α -Methyl-19-nortestosterone, pharmacokinetics, 299
- Mifepristone, effect on uterus (rabbit), 309
- Mifepristone + misoprostol, medical abortion, 167
- Minilaparotomy, female sterilization, 249
- Misoprostol, medical abortion, 353
- Multiload Cu 250, effect on lipid metabolism, 281
- Natural family planning,
 - fixed formula to define fertile window, 357
 - use of TwoDay Algorithm, 65
- Nonoxynol-9 film, acceptability, 45
- Nonoxynol-9 tablet, acceptability, 45
- Norplant[®] implants,
 - clinical study, 1, 39
 - effect on lipid metabolism, 281
 - effects on bone density and bone metabolism, 161
 - irregular uterine bleeding, 25
- Nursing women, progesterone-releasing vaginal ring, 9
- OC (oral contraceptive)
- OC trial, use of placebo control, 81
- OC use,
 - effect on back disorders, 331
 - effect on hemoglobin and ferritin levels, 101
 - risk of gestational hypertensive disorders, 145
- OC users,
 - stroke risk, 177
 - Europe vs. US studies, 177
- OCs and insulin sensitivity, 337
- Oral contraceptive (OC),
 - ethinyl estradiol + desogestrel, 151, 269
 - ethinyl estradiol + gestodene, 269, 275
 - ethinyl estradiol + levonorgestrel, 255
 - ethinyl estradiol + norethindrone acetate, 255
 - triphasic ethinyl estradiol + gestodene, 337
 - triphasic ethinyl estradiol + norethindrone, 179
 - triphasic ethinyl estradiol + norgestimate, 81, 12-3
- Ortho All-Flex[®], safety and efficacy, 71
- Ovarian function, effect of DMPA + estradiol cypionate, 189
- Ovulatory potential of follicles, effect of ethinyl estradiol + gestodene, 275
- Perfect users vs. perfect use, risk of pregnancy, 315
- Pharmacodynamic effects, DMPA + estradiol cypionate, 189
- Pharmacokinetics,
 - estradiol, 209
 - medroxyprogesterone acetate, 201, 209
 - 7 α -methyl-19-nortestosterone, 299
- Placebo controls, use in OC trial, 81

- Postcoital contraception, ethinyl estradiol +
levonorgestrel, 243
- Pregnancy risk,
 influence of cycle variability and coital frequency,
 137
 perfect users vs. perfect use, 315
- Pregnancy OC use, effect on gestational hypertensive
disorders, 145
- Progesterone-releasing vaginal ring, clinical study, 9
- Progestins nomenclature, commentary, 313
- Prostate specific antigen (PSA), semen marker of
condom failure, 289
- PSA (prostate specific antigen) 289
- Return of ovulation, following DMPA + estradiol
cypionate, 189
- Safe delivery of DMPA, use of checklist, 31
- Semen biomarker, prostate specific antigen, 289
- Spermicide, nonoxynol-9, 45
- Stroke risk, OC users, 177
- Subdermal implants (male), 7 α -methyl-19-
nortestosterone, 299
- Tamoxifen + misoprostol, medical abortion, 353
- TCu 380A,
 clinical study, 9
 effect on hemoglobin and ferritin levels, 101
- Trimonthly OC regimen, cost-effectiveness
analysis, 263
- TwoDay Algorithm, identify fertile window, 65
- Uterine activity, effect of estradiol and
 antiestrogens, 111
- Uterine bleeding, effect of mefenamic acid, 25
- Uterine myomas, effect of levonorgestrel-releasing
IUS, 51
- Uterine perforation, anchored IUD, 55
- Uterine receptivity, effect of mifepristone (rabbit),
309
- Vaginal epithelium, effect of DMPA, 15
- Vaginal ring, progesterone-releasing, 9
- Vaginal tolerance,
 Acid-buffering bioadhesive gel, 361
 nonoxynol-9, 361

K

-

0

0

